Opdivo fails Phase III CheckMate -498 trial to treat unmethylated glioblastoma multiforme . BMS
Bristol-Myers Squibb Company announced the Phase III CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM) did not meet its primary endpoint of overall survival (OS) at final analysis.
The safety profile of Opdivo was consistent with previously reported studies in solid tumors. The Company will complete a full evaluation of the data from CheckMate -498 and work with investigators on the future presentation and publication of the results.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.